TY  - JOUR
A1  - Völler, Heinz
A1  - Heyne, Karen
T1  - Evaluation of the Accuracy of the LumiraDx INR Test Using Patients in Receipt of Phenprocoumon Anticoagulation Therapy
JF  - Point of care : the journal of near-patient testing & technology
N2  - Background: The LumiraDx INR Test is a new point-of-care diagnostic test designed to analyze fingerstick blood samples. The test was assessed in patients receiving phenprocoumon (NCT04074980).
Methods: Venous plasma international normalized ratio (INR) was measured using the LumiraDx INR Test. LumiraDx INR Test-ascertained capillary whole blood INR was compared with venous plasma INR measured using the IL ACL Elite Pro and Sysmex CS-5100 reference instruments.
Results: A total of 102 patients receiving phenprocoumon were recruited. The INR results from venous plasma and capillary whole blood that were analyzed on the LumiraDx INR Test correlated well with those measured using the IL ACL Elite Pro (plasma: n = 25, r = 0.981; capillary blood: n = 74, r = 0.949) and the Sysmex CS-5100 (n = 73, r = 0.950). 
Conclusions: The LumiraDx INR Test showed high accuracy in analyzing venous plasma and capillary whole blood from patients receiving phenprocoumon.
KW  - international normalized ratio
KW  - LumiraDx Platform
KW  - LumiraDx INR Test
KW  - oral anticoagulation
KW  - point-of-care
KW  - vitamin K antagonist therapy
KW  - phenprocoumon
Y1  - 2020
U6  - https://doi.org/10.1097/POC.0000000000000207
SN  - 1533-029X
SN  - 1533-0303
VL  - 19
IS  - 3
SP  - 72
EP  - 76
PB  - Lippincott Williams & Wilkins
CY  - Philadelphia
ER  - 
TY  - JOUR
A1  - Dissmann, R.
A1  - Cromme, L. J.
A1  - Salzwedel, Annett
A1  - Taborski, U.
A1  - Kunath, J.
A1  - Gaebler, F.
A1  - Heyne, K.
A1  - Völler, Heinz
T1  - Computer aided dosage management of phenprocoumon anticoagulation therapy Clinical validation
JF  - Hämostaseologie : Organ der Gesellschaft für Thrombose- und Hämostaseforschung e.V. (GTH)
N2  - A recently developed multiparameter computer-aided expert system (TheMa) for guiding anticoagulation with phenprocoumon (PPC) was validated by a prospective investigation in 22 patients. The PPC-INR-response curve resulting from physician guided dosage was compared to INR values calculated by "twin calculation" from TheMa recommended dosage. Additionally, TheMa was used to predict the optimal time to perform surgery or invasive procedures after interruption of anticogulation therapy. Results: Comparison of physician and TheMa guided anticoagulation showed almost identical accuracy by three quantitative measures: Polygon integration method (area around INR target) 616.17 vs. 607.86, INR hits in the target range 166 vs. 161, and TTR (time in therapeutic range) 63.91 vs. 62.40 %. After discontinuation of anticoagulation therapy, calculating the INR phase-out curve with TheMa INR prognosis of 1.8 was possible with a standard deviation of 0.50 +/- 0.59 days. Conclusion: Guiding anticoagulation with TheMa was as accurate as Physician guided therapy. After interruption of anticoagulant therapy, TheMa may be used for calculating the optimal time performing operations or initiating bridging therapy.
KW  - Oral anticoagulation therapy
KW  - warfarin
KW  - phenprocoumon
KW  - computer aided dosage
KW  - expert system
Y1  - 2014
U6  - https://doi.org/10.5482/HAMO-13-06-0030
SN  - 0720-9355
VL  - 34
IS  - 3
SP  - 226
EP  - 232
PB  - Schattauer
CY  - Stuttgart
ER  -